Literature DB >> 18374593

Comparison of procalcitonin and CrP in the postoperative course after lung decortication.

Giovanni L Carboni1, Rene Fahrner, Amiq Gazdhar, Gert Printzen, Ralph Alexander Schmid, Beatrix Hoksch.   

Abstract

OBJECTIVE: The objective of this prospective study was to compare the clinical value of procalcitonin (PCT) and C-reactive protein (CrP) plasma concentrations in their postoperative course after decortication.
METHODS: Twenty-two patients requiring surgery for pleural empyema were chosen for this prospective study. Routine blood samples including CrP and PCT plasma concentrations were taken before the operation and on the 1st, 2nd, 3rd, and 7th postoperative day.
RESULTS: Due to infection PCT and CrP were elevated preoperatively. In the postoperative course both PCT and CrP reached peak-levels on day 2 with values up to 43.55 ng/ml and 384.00 mg/l, respectively. In PCT the rise was followed by a clear decrease in 20 (90.9 %) patients until day 7. In contrast the CrP levels decreased slowly and only seven (54.5%) patients had values of 100 mg/l or below on day 7. PCT showed a better correlation with the clinic in case of septic course than CrP does.
CONCLUSIONS: PCT reflects postoperative clinical course more accurately than CrP. Therefore, PCT is a more appropriate laboratory parameter to monitor patients after surgery for pleural empyema.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374593     DOI: 10.1016/j.ejcts.2008.02.013

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  The rapidly expanding role of procalcitonin as a diagnostic and prognostic assay besides in UTIs.

Authors:  Shailendra Kapoor
Journal:  Int Urol Nephrol       Date:  2009-01-08       Impact factor: 2.370

2.  Procalcitonin as preoperative marker for surgery in advanced parapneumonic empyema.

Authors:  Claudio Caviezel; Philipp Schuetz; Stephan Gerdes; Franco Gambazzi
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

3.  Serum value of procalcitonin as a marker of intestinal damages: type, extension, and prognosis.

Authors:  C Cosse; C Sabbagh; F Browet; F Mauvais; L Rebibo; E Zogheib; D Chatelain; S Kamel; J M Regimbeau
Journal:  Surg Endosc       Date:  2015-02-21       Impact factor: 4.584

4.  Imaging and Clinical Parameters for Distinction between Infected and Non-Infected Fluid Collections in CT: Prospective Study Using Extended Microbiological Approach.

Authors:  Christopher Skusa; Romy Skusa; Moritz Wohlfarth; Philipp Warnke; Andreas Podbielski; Kristina Bath; Justus Groß; Clemens Schafmayer; Hagen Frickmann; Marc-André Weber; Andreas Hahn; Felix G Meinel
Journal:  Diagnostics (Basel)       Date:  2022-02-14

5.  Procalcitonin as a predictive marker for surgical site infection in elective colorectal cancer surgery.

Authors:  Yuji Takakura; Takao Hinoi; Hiroyuki Egi; Manabu Shimomura; Tomohiro Adachi; Yasufumi Saito; Naoki Tanimine; Masashi Miguchi; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2013-06-20       Impact factor: 3.445

6.  Evaluation of serial C-reactive protein measurements after surgical treatment of pleural empyema.

Authors:  Israel Lopes Medeiros; Ricardo Mingarini Terra; Esther Mihwa Choi; Paulo Manuel Pego-Fernandes; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

7.  Evaluation of procalcitonin as a biomarker of diagnosis, severity and postoperative complications in adult patients with acute appendicitis.

Authors:  Mohammad Vaziri; Fahimeh Ehsanipour; Abdolreza Pazouki; Zeinab Tamannaie; Roohollah Taghavi; Mohaddese Pishgahroudsari; Fatemeh Jesmi; Shahla Chaichian
Journal:  Med J Islam Repub Iran       Date:  2014-07-07

8.  Role of biomarkers in early infectious complications after lung transplantation.

Authors:  Borja Suberviola; Luzdivina Rellan; Jordi Riera; Reyes Iranzo; Ascension Garcia Campos; Juan Carlos Robles; Rosario Vicente; Eduardo Miñambres; Miguel Santibanez
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.